Placebo controlled
Sponsors
Department of Health, Instituto de Cardiologia do Rio Grande do Sul, Evans Fernandez Perez, Boehringer Ingelheim
Conditions
Amblyopia
Eye Diseases
Visual disurbancesInflammatory Disorder of the Cardiovascular SystemInterstitial Lung DiseaseNASH (niet alcoholische steatose hepatitis)
Non alcoholic liver inflammation
Non alcoholic steatohepatitis
Phase 2
Polyphenols Supplementation on Prostaglandin E2 in Women - Randomized Clinical Trial
CompletedNCT02567617
Start: 2014-05-31End: 2015-03-31Updated: 2015-10-05
Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis
TerminatedNCT02958917
Start: 2017-06-05End: 2021-03-02Updated: 2023-01-09
A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.
Active, not recruitingNL-OMON47669
Start: 2019-01-08Target: 2Updated: 2024-02-28